###### Strengths and limitations of this study

-   This cohort is the first comprehensive source of health data compiled from people living with HIV in Manitoba and will provide important opportunities for understanding clinical care needs, gaps and outcomes of people living with HIV in the province.

-   Cohort enrolment protocols are clinic based, and as such, this cohort may not be representative of people living with HIV who are suboptimally engaged in care. One key strategy to circumvent the misinterpretation of analyses derived from cohort data will be to involve Manitoba HIV Program's clients and their providers in the analysis, interpretation and knowledge translation processes.

-   Because this cohort is embedded within the Manitoba HIV Program, and stakeholders within government and the community of people with lived experience are actively involved in its development, the data from the cohort will be able to facilitate analyses that can inform programming and provincial policy on adequately resourcing HIV-related health services.

Introduction {#s1}
============

Annual reports on HIV in Canada consistently highlight heterogeneous, although relatively stable, epidemiological trends across the country.[@R1] At the end of 2016, the Public Health Agency of Canada (PHAC) estimated that 63 110 people were living with HIV in the country and 2402 people were newly diagnosed in 2017.[@R1] Nationally, new HIV diagnoses disproportionately occur among Indigenous (First Nations, Inuit and Métis) populations and people who have immigrated from countries where HIV is endemic.[@R1] The greatest proportion of prevalent HIV infections in nearly all Canadian provinces is attributed to condomless sex between men; however, notable exceptions include the central Prairie provinces of Saskatchewan and Manitoba, where most incident and prevalent cases are attributable to injection drug use and heterosexual transmission, respectively.[@R2] The rates of new HIV diagnoses per 100 000 population in Manitoba have been consistently higher than the national average, ranging from 9.5 new diagnoses in 2014 to 6.6 in 2016 and 2017.[@R1] Despite evidence of unique epidemiology and disproportionately high rates of infection, relatively little research addresses HIV epidemiology in the Canadian Prairies,[@R6] and there is a specific lack of published research focusing on Manitoba.

Current HIV epidemiological data for Manitoba are primarily derived from surveillance reports produced by PHAC and the provincial health department, Manitoba Health, Seniors and Active Living (MHSAL).[@R1] In 2017, MHSAL reported 89 new cases of HIV in the province with the majority of cases occurring in Winnipeg (81%) and a disproportionately high incidence among women when compared with national rates.[@R2] While useful for providing basic information about patterns and trends in HIV infection in Manitoba, these reports only provide aggregate-level demographic and geographic analyses of the previous year's incident infections (new diagnoses and/or cases introduced to, but not acquired in, the province). Without the clinical data, these reports are limited in their ability to inform specific research questions or programmatic decisions for HIV care and service delivery in the province.

In 2013, as part of a Canadian Institutes of Health Research-funded programme of research, the 'Advancing Primary Healthcare for Persons Living with HIV in Canada' (LHIV) study provided support for the establishment of a prospective clinical cohort of people living with HIV in Manitoba. This clinical cohort is the first comprehensive source of HIV-specific health data in Manitoba and provides important opportunities to address key knowledge gaps in local HIV epidemiology---including patterns of healthcare utilisation and relevant clinical outcomes---and to understand healthcare needs of people living with HIV in the province. Similar cohorts have been developed and are now are well-established in other Canadian provinces, including British Columbia[@R7] and Ontario.[@R8] This article provides an overview of processes and procedures involved in cohort development and maintenance, and describes demographic-related and HIV-related characteristics of LHIV-Manitoba cohort participants.

Cohort description {#s2}
==================

Study setting {#s2-1}
-------------

Established in 2007, the Manitoba HIV Program is the primary provider of treatment, care and support for people living with HIV in the province. The Manitoba HIV Program employs a multidisciplinary care model in which HIV specialist physicians, family physicians, nurses (including nurse practitioners), pharmacists, dietitians, social workers and other allied service providers provide comprehensive HIV care out of three clinic sites---a hospital-based outpatient clinic and a community health centre in Manitoba's capital city, Winnipeg, and a nurse-run health access centre in Brandon, a semi-urban city approximately 200 km west of Winnipeg. While all three clinic sites follow a multidisciplinary care model and each have links to health promotion programmes and resources, some differences in organisation exist. For example, the clinic at the community health centre is run by family doctors and each client at that site is assigned to a specific physician and nurse couple. Meanwhile, physicians at the hospital-based clinic are infectious disease specialists and all clients of the hospital clinic in Winnipeg and the nurse-run clinic in Brandon are seen by a rotating roster of providers.

Patient and public involvement {#s2-2}
------------------------------

Although arising from a research project, the LHIV-Manitoba cohort is strategically embedded within the Manitoba HIV Program and the local study team partners with stakeholders within the Manitoba HIV Program and other community clinics, MHSAL, the Manitoba First Nations AIDS Working Group and the LHIV study's Community Scholar Program,[@R9] all of whom have been actively involved in the development of the cohort. Study design and enrolment procedures were conducted by researchers and trainees within the LHIV study team. Throughout the development of the cohort, engagement through community forums and meetings with key stakeholders provided information about the objectives of the LHIV-Manitoba cohort and what it meant to be a participant, while actively seeking input about research questions that could be addressed using cohort data. As such, findings from cohort data are expected to have direct relevance and applicability for both HIV care programming and provincial health policy. Dissemination and knowledge translation activities with all key stakeholders, including community members, community-based organisations and key policy-makers and decision-makers, will be facilitated by study team members and Manitoba HIV Program staff.

Enrolment procedures {#s2-4}
--------------------

Recruitment began at one clinic site in October 2013 and was fully implemented across all Manitoba HIV Program sites by January 2014. Data collection, linkage to administrative health databases and data cleaning and analyses began in early 2017. Both enrolment and linkage are ongoing.

The enrolment process is illustrated in [figure 1](#F1){ref-type="fig"}. Inclusion criteria for the cohort are broad: participants must be at least 18 years of age and either living with HIV in Manitoba or receiving HIV care in Manitoba. Individuals who met these criteria but are under the jurisdiction of the Public Guardian and Trustee of Manitoba, or were otherwise unable to make decisions pertaining to their own healthcare, are deemed ineligible for participation in the cohort.

![Recruitment, informed consent and data collection processes for the LHIV-Manitoba cohort.](bmjopen-2019-034259f01){#F1}

Recruitment and informed consent procedures take place within the Manitoba HIV Program clinics; clients who present to clinic are approached by a nurse or another allied healthcare provider and asked whether they are willing to speak to a research assistant about participating in a research project. If a client is agreeable, a research assistant meets with them to explain the purpose, context and methods for the LHIV-Manitoba cohort study, and reviews the informed consent form to determine whether the person is interested, willing and able to participate. Participants have the opportunity to take part in any combination of three separate components of the LHIV-Manitoba cohort: (1) have their clinical data collected; and/or (2) have their clinical data linked to administrative health data that is routinely collected by the province; and/or (3) indicate interest in being approached about future HIV research studies. Clients who are not ready to decide immediately can defer their decision to participate in the cohort and request to meet with the research assistant at a later date to reconsider their participation. Study staff keeps track of individuals who asked to defer their decision to participant and actively follow-up with them at their next clinic appointment in a year's time, depending on the stated preference.

Study measures, data sources and data collection {#s2-5}
------------------------------------------------

Clinical data are manually extracted from electronic medical records (EMR)---or from paper charts for clinical information recorded prior to the introduction of EMR to clinic sites---within the Manitoba HIV Program's clinic sites by the first author and two trained extractors, and then entered into an encrypted, password protected Excel spreadsheet for consenting participants. Standardised definitions were developed for each variable to ensure quality and consistency of data abstracted from clinical records. Manitoba HIV Program's clinicians who had entered data into clinical records were consulted for instances in which information to be collected was unclear or ambiguous. A complete clinical dataset for the LHIV-Manitoba cohort includes variables on participants' sociodemographic characteristics (age, sex, geographic location of residence and self-identified ethnicity), comorbid chronic and mental health diagnoses, opportunistic infections, and other co-infections (occurring within 6 months of presentation to HIV care), including Hepatitis C virus (HCV); recorded HIV exposure categories; date and geographic location of first positive HIV test; CD4 count at time of diagnosis, at time of antiretroviral therapy (ART) initiation, and at the end of the second and fourth quarters of each year, beginning in 2017; date of first ART initiation; current ART regimen (collected biannually, beginning in 2017); alcohol and drug use, including injection drug use; and type of prescription pharmaceutical insurance coverage (collected biannually, beginning in 2017).

The study's institutional ethics approvals also allow data from deceased clients of the Manitoba HIV Program to be collected via retrospective chart reviews. A limited dataset is extracted from clinical records of deceased individuals, which comprises a subset of the aforementioned clinical datasets, excluding all comorbidity and co-infection data from clinical records, except for HCV, treatment regimen data and prescription pharmaceutical insurance data. Including data from deceased clients provides an important opportunity to explore and better understand determinants of mortality among people living with HIV in Manitoba. This has been identified as an area of particular interest to the Manitoba HIV Program, which, up to now, has not been adequately explored. Furthermore, the inclusion of these data helps to ensure broader generalisability of our findings from the cohort.

For individuals who were enrolled posthumously, and for participants who provide consent to data linkage, anonymised, de-identified clinical data are linked to provincial administrative health databases housed at MHSAL. Manitoba's administrative health datasets include individual-level records for nearly all contacts with the provincial healthcare system, including physician visits, hospital admissions, pharmaceutical prescription dispensations and laboratory testing.[@R10] Linkage between clinical and administrative datasets is done through matching an individual's unique Personal Health Identification Number (PHIN) within both datasets. Before linked datasets are returned to the study team, MHSAL scrambles PHINs to de-identify the datasets and maintain participant anonymity.[@R11]

Characteristics of study participants {#s2-6}
-------------------------------------

As of 31 March 2019, 890 unique individuals are included in the cohort ([figure 1](#F1){ref-type="fig"}). A complete clinical dataset exists for 725 (81.5%) cohort participants who agreed to have their data reviewed and extracted from clinical records within the Manitoba HIV Program. A limited clinical dataset exists for an additional 165 individuals whose clinical records were reviewed posthumously. Nearly, all individual-level clinical data are also linked to provincial administrative health datasets (n=868, 97.5%). At the end of the first quarter of 2019, 676 cohort participants (76.0%) were alive and 214 (24.0%) were deceased.

Select sociodemographic characteristics and outcomes of cohort participants are presented in [table 1](#T1){ref-type="table"} and compared with the larger Manitoba HIV Program's client population. The average age of cohort participants at the end of the first quarter of 2019 (or at time of death, for participants who were deceased by 31 March 2019) was 49.7±11.9 years. The majority of cohort participants are male (71.2%), over 80% reported being either white (42.4%) or Indigenous (41.6%), while an additional 10.9% self-identified as an ethnicity categorised as African/Caribbean/black. The geographic distribution of cohort participants is primarily concentrated in Winnipeg (80.8%), while 1.4% of cohort participants live outside of Manitoba.

###### 

Sociodemographic characteristics and key outcomes of LHIV-Manitoba cohort participants, as compared with Manitoba HIV Program's client population

  ---------------------------------------------------------------------------------------------------------------------------------
                                                           LHIV-Manitoba cohort\   Manitoba HIV Program\   P value          
                                                           (N=890)                 (N=1357)                                 
  -------------------------------------------------------- ----------------------- ----------------------- --------- ------ -------
  **Age (years) on 31 March 2019 or at time of death**                                                                      

  \<18                                                     0                       0                       2         0.2    0.245

  18--24                                                   10                      1.1                     46        3.4    0.001

  25--39                                                   178                     20.0                    358       26.4   0.001

  40--64                                                   621                     69.8                    871       64.2   0.006

  ≥65                                                      81                      9.1                     78        5.8    0.003

  Mean (SD)                                                49.7 (11.9)             46.8 (12.1)             0.000            

  Median (IQR)                                             49.8 (41.5--57.5)       46.9 (37.9--55.2)       0.000            

  **Sex**                                                                                                                   

  Male                                                     634                     71.2                    878       64.7   0.001

  Female                                                   256                     28.8                    478       35.2   0.002

  **Self-identified ethnicity**\*                                                                                           

  White                                                    376                     42.4                    407       36.2   0.000

  Indigenous (First Nations, Inuit and Métis)              369                     41.6                    448       39.9   0.000

  Sub-Saharan African/Caribbean/black                      97                      10.9                    214       19.1   0.001

  Other†                                                   44                      5.0                     54        4.8    0.307

  **Region of residence**                                                                                                   

  Winnipeg                                                 719                     80.8                    1080      79.6   0.486

  Central and Eastern Manitoba                             48                      5.4                     71        5.2    0.836

  Southern Manitoba                                        37                      4.2                     67        4.9    0.440

  Western Manitoba                                         35                      3.9                     64        4.7    0.365

  Northern Manitoba                                        30                      3.4                     46        3.4    1.000

  Out of province                                          12                      1.4                     21        1.6    0.705

  Unknown/No known address                                 9                       1.0                     8         0.6    0.285

  **Drug coverage at 31 March 2019**‡                                                                                       

  Out-of-pocket expenses associated with drug plan         293                     45.4                    --        --     --

  No out-of-pocket expenses associated with drug plan      346                     53.6                    --        --     

  Not on treatment/unknown                                 6                       0.9                     --        --     

  **Problematic substance use recorded in clinic file**§                                                                    

  Alcohol                                                  292                     40.3                    --        --     --

  Illegal or 'street' drugs¶                               222                     31.6                    --        --     

  Alcohol and drugs                                        148                     21.1                    --        --     

  **Has a primary care practitioner**§                     627                     70.5                    --        --     --
  ---------------------------------------------------------------------------------------------------------------------------------

\*Sample sizes may not add up to total participants due to missing data for some variables.

†Includes Latin American, East/Southeast Asian, South Asian and West Asian/North African/Middle Eastern.

‡Variable only collected for participants alive in the fourth quarter of 2018 (n=645).

§Variable only collected for participants alive at cohort enrolment (n=725).

¶Includes cocaine, crack cocaine, heroin, crystal methamphetamine, other hallucinogens (lysergic acid diethylamide (LSD), γ-hydroxybutyric acid (GHB), ketamine, 3,4-methylenedioxymethamphetamine (ecstasy)) and solvents such as Talwin and Ritalin and alkyl nitrates (poppers).

Findings to date {#s3}
================

Analyses from the LHIV-Manitoba cohort are ongoing; a summary of preliminary findings is provided below.

Representativeness and distribution of key outcomes within the LHIV-Manitoba cohort {#s3-1}
-----------------------------------------------------------------------------------

Given the research and programmatic potential of this cohort, it is of particular interest to understand whether, and to what extent, the demographic profile of cohort participants is representative of the larger Manitoba HIV Program client population ([table 1](#T1){ref-type="table"}). Although similar in age structure, compared with the Manitoba HIV Program's client population, cohort participants are significantly more likely to be ≥40 years (78.9% vs 70.0%, p\<0.05). Compared with the Manitoba HIV Program, the cohort includes significantly more men (71.2% vs 64.7%; p=0.001) and individuals who self-identify as white (42.3% vs 30.0%, p\<0.001) or Indigenous (41.5% vs 33.0%, p\<0.001) are greater in the LHIV-Manitoba cohort, while African/Caribbean/black clients are underrepresented (10.9% vs 15.8%, p\<0.001). The geographic distribution of cohort participants is similar to that of the larger client population, with the large majority of participants residing in Winnipeg (80.8% vs 79.6%, p=0.486).

HIV-specific clinical indicators, co-infections and comorbidities {#s3-2}
-----------------------------------------------------------------

Selected clinical indicators, analysed by sex, are presented in [table 2](#T2){ref-type="table"}. Preliminary findings from cohort participants' clinical data highlight similar trends to those seen in the most recent Manitoba HIV Program's annual reports.[@R12] While a substantial proportion of cohort participants presented late to HIV care, with 57.0% having initial CD4 counts≤350 cells/mm^3^, 52.3% of most recent CD4 counts are \>500 cells/mm^3^. In general, the proportion of participants with suppressed viral loads (\<200 HIV RNA copies/mL) increased from their initial to most recent clinic visit (50.5% to 83.2%, respectively). Female cohort participants were significantly more likely than male participants to have unsuppressed viral loads (ie, \>200 copies/mL) at presentation to care, but this same difference was not seen when analysing most recent viral load results. Opportunistic infections (OIs) were diagnosed at or within 6 months of presentation to HIV care among 29.1% of participants who were alive at enrolment, and 6.6% presented to care with ≥2 OIs. Prevalence of active HCV co-infection at enrolment is 17.5% among all participants, and slightly higher among female than male participants (19.9% vs 16.6%). Two-fifths of participants had at least one comorbidity recorded in their clinical records, and 12.8% (n=93) were living with at least two.

###### 

HIV-specific and other clinical indicators among LHIV-Manitoba cohort participants, by sex

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                            Male\*\                 Female\*\             Total\*\                P value                
                                                            (N=634)                 (N=256)               (N=890)                                        
  --------------------------------------------------------- ----------------------- --------------------- ----------------------- --------- ----- ------ --------
  **Initial CD4 count in Manitoba (cells/mm^3^**)                                                                                                        

  \<200                                                     211                     33.8                  72                      28.7      283   32.3   0.467

  200--350                                                  151                     24.2                  65                      25.9      216   24.7   

  351--500                                                  117                     18.8                  47                      18.7      164   18.7   

  \>500                                                     145                     23.2                  67                      26.7      212   24.2   

  Mean (SD)                                                 328.2 (248.7)           370.5 (257.1)         340.3 (251.7)                                  

  Median (IQR)                                              298.5 (116--478.5)      336 (179--517)        316 (129--492)                                 

  **Last CD4 count, up to the end of 2018 (cells/mm^3^**)                                                                                                

  \<200                                                     81                      12.8                  47                      18.6      128   14.5   0.064

  200--350                                                  88                      14.0                  38                      15.0      126   14.3   

  351--500                                                  130                     20.6                  38                      15.0      168   19.0   

  \>500                                                     332                     52.6                  130                     51.4      462   52.3   

  Mean (SD)                                                 589.3 (303.6)           331.7 (302.0)         542.2 (319.1)                                  

  Median (IQR)                                              565 (384--768)          256 (99--472)         517.5 (309.5--735.5)                           

  **Initial viral load (copies/mL**)                                                                                                                     

  \<200                                                     329                     54.7                  100                     40.3      429   50.5   0.001†

  200--999                                                  27                      4.5                   16                      6.5       43    5.1    

  1000--99 999                                              147                     24.5                  90                      36.3      237   27.9   

  100 000--999 999                                          80                      13.3                  36                      14.5      116   13.7   

  ≥1 000 000                                                18                      3.0                   6                       2.4       24    2.8    

  Mean (SD)                                                 125 778.7 (523 975.9)   107 972 (340 114.2)   120 577.2 (477 511.4)                          

  Median (IQR)                                              60.9 (0--38 400)        1875 (0--40 300)      170 (0--38 800)                                

  **Last viral load, up to the end of 2018 (copies/mL**)                                                                                                 

  \<200                                                     491                     84.4                  190                     80.2      681   83.2   0.517†

  200--999                                                  22                      3.8                   9                       3.8       31    3.8    

  1000--99 999                                              46                      7.9                   28                      11.8      74    9.0    

  100 000--999 999                                          18                      3.1                   8                       3.4       26    3.2    

  ≥1 000 000                                                5                       0.9                   2                       0.8       7     0.9    

  Mean (SD)                                                 40 972 (415 359.2)      27 705 (171 693.3)    37 133.2 (362 048.3)                           

  Median (IQR)                                              0 (0--27.9)             0 (0--54.6)           0 (0--32.4)                                    

  **Opportunistic infections (OI)**‡§                                                                                                                    

  None                                                      364                     69.9                  150                     73.5      514   70.9   0.131†

  Oropharyngeal and/or oesophageal candidiasis (thrush)     108                     20.7                  39                      19.1      147   20.3   

  *Pneumocystis jirovecii* pneumonia                        56                      10.8                  9                       4.4       65    9.0    

  Active tuberculosis                                       29                      5.6                   14                      6.9       43    5.9    

  *Mycobacterium avium* intracellulare                      7                       1.3                   1                       0.5       8     1.1    

  Cryptococcal meningitis                                   4                       0.8                   1                       0.5       5     0.7    

  **Hepatitis C virus status at cohort enrolment**                                                                                                       

  No infection                                              496                     78.2                  182                     71.1      678   76.2   0.085†

  Active infection (RNA+)                                   105                     16.6                  51                      19.9      156   17.5   

  Past infection (RNA−/Ab+)                                 32                      5.1                   22                      8.6       54    6.1    

  Unknown                                                   1                       0.2                   1                       0.4       2     0.2    

  **Comorbidities‡**¶                                                                                                                                    

  None                                                      305                     58.5                  125                     61.3      430   59.3   0.006†

  Asthma/Chronic obstructive pulmonary disease (COPD)       93                      17.9                  36                      17.7      129   17.8   

  Hypertension                                              88                      16.9                  24                      11.8      112   15.5   

  Type II diabetes                                          66                      12.7                  39                      19.1      105   14.5   

  Coronary artery disease                                   33                      6.3                   3                       1.5       36    5.0    
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Sample sizes may not add up to total participants due to missing data for some variables.

†Some expected values \<5, so p values must be interpreted with caution.

‡Variable only collected for participants who were alive at cohort enrolment: male, n=521; female, n=204 and total, n=725.

§Diagnosed at, or within 6 months of presentation to care with the Manitoba HIV Program. Sum of categories exceeds total sample size because some participants presented with ≥1 OI.

¶Sum of categories exceeds total sample size because some participants presented with ≥1 comorbidity.

HIV exposures among cohort participants {#s3-3}
---------------------------------------

[Table 3](#T3){ref-type="table"} presents all self-reported HIV exposure categories recorded in participants' clinical files, analysed by sex. Although data in [table 3](#T3){ref-type="table"} are organised according to an HIV 'risk hierarchy'---through which participants' primary risk exposure categories are assigned according to an established hierarchy of risk factors[@R14]---we report multiple exposure categories per individual in order to capture some of the complexity that can be missed with conventional hierarchy frameworks.[@R15] Notably, 41.0% of female participants reported at least two possible HIV exposure categories, while 29.6% of men reported the same. Similar to trends from annual surveillance reports in Manitoba,[@R2] condomless vaginal sex is the most commonly identified exposure category. Nearly, half of the male participants (47.6%) reported condomless anal sex with other men as a possible exposure, and 4.4% reported both condomless anal sex with men and injection drug use. The majority of female participants (92.6%) reported condomless vaginal sex as a possible exposure, and 26.2% reported injection drug use.

###### 

Self-identified HIV exposure categories among LHIV-Manitoba cohort participants, by sex

  ----------------------------------------------------------------------------------------------------------------------------------------
                                                             Male\*\   Female\*\   Total\    P value                         
                                                             (N=634)   (N=256)     (N=890)                                   
  ---------------------------------------------------------- --------- ----------- --------- ---------- --------- ---------- -------------
  **Condomless anal sex between males+injection drug use**   **28**    **4.4**     **--**    **--**     **28**    **3.1**    **--**

  **Condomless anal sex between males**                      **302**   **47.6**    **--**    **--**     **302**   **33.9**   **--**

  Recipient of blood/blood product                           3         1.0         --        --         3         0.3        

  Condomless vaginal sex                                     50        16.6        --        --         50        5.6        

  Possible exposure in an HIV-endemic country†               5         1.7         --        --         5         0.6        

  Occupational exposure                                      2         0.7         --        --         2         0.2        

  **Injection drug use**                                     **126**   **19.9**    **67**    **26.2**   **193**   **21.7**   **0.039**

  Recipient of blood/blood product                           5         4.0         2         3.0        7         0.8        

  Condomless vaginal sex                                     80        63.5        56        83.6       136       15.3       

  Possible exposure in an HIV-endemic country†               1         0.8         0         0          1         0.1        

  Occupational exposure                                      1         0.8         1         1.5        2         0.2        

  **Recipient of blood/blood product**                       **18**    **2.0**     **8**     **0.9**    **26**    **2.9**    **0.248**

  Condomless vaginal sex                                     11        61.1        6         75.0       17        1.9        

  Possible exposure in an HIV-endemic country†               2         11.1        1         12.5       3         0.3        

  Occupational exposure                                      1         5.6         2         25.0       3         0.3        

  **Condomless vaginal sex**                                 **331**   **52.2**    **237**   **92.5**   **568**   **63.8**   **\<0.001**

  Possible exposure in an HIV-endemic country†               35        10.6        40        15.6       75        8.4        

  Occupational exposure                                      2         0.6         4         1.7        6         0.7        

  **Occupational exposure**                                  **5**     **0.8**     **4**     **1.6**    **9**     **1.0**    **0.285**

  Possible exposure in an HIV-endemic country                0         0           0         0          0         0          

  **Possible perinatal acquisition**                         **1**     **0.2**     **0**     **0**      **1**     **0.1**    **--**

  Possible exposure in an HIV-endemic country†               1         100         --        --         1         0.1        

  **Other/unknown**                                          **16**    **2.5**     **7**     **2.7**    **23**    **2.6**    **0.864**

  **Number of potential HIV exposures recorded**                                                                             

  1                                                          446       70.4        151       59.0       597       67.1       \<0.001

  2                                                          172       27.1        102       39.8       274       30.8       

  ≥3                                                         16        2.5         3         1.2        19        2.1        
  ----------------------------------------------------------------------------------------------------------------------------------------

\*Sum of categories exceeds total sample size because participants may have ≥1 HIV exposure category reported in clinical file.

†Possible exposure in an HIV-endemic country is never assigned as a primary exposure category, but is captured as an additional exposure category if an individual was born in, or spent considerable time living/working in an HIV-endemic country and experienced a potentially 'risky' event.

Strengths and limitations {#s4}
=========================

Key limitations and challenges experienced throughout the development of the LHIV-Manitoba cohort, and the particular challenges associated with developing clinical cohorts using research dollars, have been described in detail elsewhere.[@R17] Briefly, a number of participants expressed apprehension about the kinds of data that would be collected as a result of their involvement with the cohort, and in response, study staff made a point to spend adequate time to clearly explain the processes through which the study is able to link clinical and administrative data while maintaining confidentiality. Additionally, efficiently implementing study protocols without disrupting existing clinic operations was another substantial challenge; incorporating additional procedures related to cohort enrolment into routine encounters was difficult for healthcare providers who are working within busy HIV clinics. The study team regularly engages with providers to highlight the benefits that the cohort may confer to their own practice, their clients' needs and the operations of Manitoba HIV Program.

Because enrolment protocols are clinic based, this cohort may not be representative of people living with HIV who are suboptimally engaged in care. As enrolment efforts move forward, it will be important for the study team to consider strategies to increase the proportion of participants belonging to demographic subgroups who are currently underrepresented in the cohort. It is of particular interest to the study team to understand whether certain subgroups are less likely to consent to cohort participation, and if so, why. While findings from the cohort will still be important for informing care programming and policy decisions for the province, generalisability may be limited, and results must be interpreted accordingly. One key strategy to circumvent the misinterpretation of analyses derived from cohort data will be to involve Manitoba HIV Program's clients and their providers in the analysis, interpretation and knowledge translation processes.

The LHIV-Manitoba cohort is the first comprehensive source of health data compiled from people living with HIV in the province and will provide important opportunities for systematically and comprehensively understanding clinical care needs, gaps and outcomes of Manitobans living with HIV. Importantly, Manitoba is well positioned to undertake large, population-based linkage studies given the existence of a single insurer (MHSAL) that is responsible for payment of most health services, and the existence of linkable, population-based administrative health databases through the Manitoba Centre for Health Policy.[@R18] The cohort also identifies common comorbidities such as diabetes and hypertension, where further assessment of outcomes offers opportunities for targeted resource allocation for improved management. Furthermore, the Manitoba HIV Program embodies a unique care model---comprising both specialist and primary care services---that closely aligns with the Patient-Centred Medical Home model of HIV care.[@R20] As such, findings from the LHIV-Manitoba cohort will be able to speak to the growing body of literature focusing on holistic models of HIV care delivery.[@R20]

Finally, because the clinical cohort is embedded within the Manitoba HIV Program, and stakeholders within MHSAL and the community of people with lived experience have been actively involved in its development, we also expect that data from the cohort will facilitate epidemiological analyses that can inform both HIV care programming and provincial policy on adequately resourcing HIV-related health services.

Future plans {#s5}
============

Future analyses using clinical cohort data will focus on areas that have been identified as specific points of interest for the Manitoba HIV Program, namely, generating a better understanding of the impact of existing provincial drug plans on clinical outcomes and exploring, for the first time in the province, characteristics and determinants of mortality among people living with HIV. Additionally, the cohort data are currently being used to generate Manitoba-specific HIV care cascade estimates,[@R22] which will be presented in detail in a forthcoming manuscript. The subsequent work will examine the local HIV care cascade through an equity lens to better understand how different groups of participants experience HIV care and treatment outcomes differently within Manitoba.
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